{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:23:37Z","timestamp":1791318217018,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173902"],"award-info":[{"award-number":["82173902"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104274"],"award-info":[{"award-number":["82104274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874326"],"award-info":[{"award-number":["81874326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xphs.2024.11.020","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T17:55:20Z","timestamp":1734371720000},"page":"1087-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics and safety of pirfenidone in individuals with chronic kidney disease stage G2 and G3a: A single-dose, Phase I, bridging study"],"prefix":"10.1016","volume":"114","author":[{"given":"Dianwen","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.11.020_bib0001","first-page":"A253","article-title":"Safety of combined pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis","volume":"72","author":"Flaherty","year":"2017","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.xphs.2024.11.020_bib0002","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10082","key":"10.1016\/j.xphs.2024.11.020_bib0003","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2024.11.020_bib0004","doi-asserted-by":"crossref","first-page":"104481","DOI":"10.1016\/j.ebiom.2023.104481","article-title":"Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability","volume":"90","author":"Nambiar","year":"2023","journal-title":"Ebiomedicine"},{"key":"10.1016\/j.xphs.2024.11.020_bib0005","doi-asserted-by":"crossref","first-page":"846300","DOI":"10.3389\/fmed.2022.846300","article-title":"Highlights of strategies targeting fibroblasts for novel therapies for rheumatoid arthritis","volume":"9","author":"Chu","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.xphs.2024.11.020_bib0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.23876\/j.krcp.22.033","article-title":"Diminazene aceturate exacerbates renal fibrosis after unilateral ureteral obstruction in female mice","volume":"42","author":"Kim","year":"2023","journal-title":"Kidney Res Clin Pract"},{"issue":"22","key":"10.1016\/j.xphs.2024.11.020_bib0007","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.xphs.2024.11.020_bib0008","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/cts.13419","article-title":"Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects","volume":"15","author":"Nawa","year":"2022","journal-title":"Cts-Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.11.020_bib0009","first-page":"85","article-title":"Combined pirfenidone, azithromycin and prednisolone in post-h1n1 ards pulmonary fibrosis","volume":"35","author":"Saha","year":"2018","journal-title":"Sarcoidosis Vasculit Diffuse Lung Dis"},{"issue":"160","key":"10.1016\/j.xphs.2024.11.020_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0050-2021","article-title":"Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review","volume":"30","author":"Bos","year":"2021","journal-title":"Eur Respirat Rev"},{"key":"10.1016\/j.xphs.2024.11.020_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1755-1536-3-16","article-title":"The multifaceted role of pirfenidone and its novel targets","volume":"3","author":"Macias-Barragan","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"6","key":"10.1016\/j.xphs.2024.11.020_bib0012","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1167\/iovs.09-4257","article-title":"Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels","volume":"51","author":"Kim","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.11.020_bib0013","article-title":"Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin","volume":"40","author":"Demirkol","year":"2023","journal-title":"Sarcoidosis, Vascul Diffuse Lung Dis: Off J WASOG"},{"issue":"8","key":"10.1016\/j.xphs.2024.11.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1449","article-title":"Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: a single-arm, open-label nonrandomized study","volume":"6","author":"Jastrzebski","year":"2023","journal-title":"Health Sci Rep"},{"issue":"4","key":"10.1016\/j.xphs.2024.11.020_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.trsl.2014.07.010","article-title":"Therapeutic targets for treating fibrotic kidney diseases","volume":"165","author":"Lee","year":"2015","journal-title":"Transl Res"},{"issue":"2","key":"10.1016\/j.xphs.2024.11.020_bib0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1191\/1352458505ms1134oa","article-title":"A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis","volume":"11","author":"Walker","year":"2005","journal-title":"Multiple Sclerosis J"},{"issue":"11","key":"10.1016\/j.xphs.2024.11.020_bib0017","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/gut.2006.107136","article-title":"A pilot study in patients with established advanced liver fibrosis using pirfenidone","volume":"55","author":"Armendariz-Borunda","year":"2006","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.xphs.2024.11.020_bib0018","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10067-022-06466-8","article-title":"Effective therapy of pirfenidone in a patient with idiopathic retroperitoneal fibrosis: report of a case","volume":"42","author":"Zhao","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.xphs.2024.11.020_bib0019","first-page":"233","article-title":"Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model","author":"Qiu","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.xphs.2024.11.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120185","article-title":"Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor","volume":"288","author":"Hazem","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.xphs.2024.11.020_bib0021","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1364-4","article-title":"Pirfenidone prevents acute kidney injury in the rat","volume":"20","author":"Lima-Posada","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.xphs.2024.11.020_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.879890","article-title":"Global, regional and national burden of cancers attributable to high fasting plasma glucose in 204 countries and territories, 1990-2019","volume":"13","author":"Safiri","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.xphs.2024.11.020_bib0023","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes - UK prospective diabetes study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.xphs.2024.11.020_bib0024","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.xphs.2024.11.020_bib0025","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0091270007304104","article-title":"Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers","volume":"47","author":"Shi","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2024.11.020_bib0026","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0033-1341478","article-title":"Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions","volume":"63","author":"Huang","year":"2013","journal-title":"Drug Res"},{"issue":"6","key":"10.1016\/j.xphs.2024.11.020_bib0027","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40262-023-01250-6","article-title":"Multicenter population pharmacokinetics and exposure-efficacy analysis of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"62","author":"Wang","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2024.11.020_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492400546X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492400546X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T22:09:45Z","timestamp":1742681385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492400546X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S002235492400546X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.11.020","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety of pirfenidone in individuals with chronic kidney disease stage G2 and G3a: A single-dose, Phase I, bridging study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}